Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 7.08% and Operating profit at -55.78% over the last 5 years
2
The company has declared Negative results for the last 5 consecutive quarters
3
Risky -
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 14,381 Million (Large Cap)
196.00
NA
0.70%
-0.04
0.76%
1.50
Revenue and Profits:
Net Sales:
733 Million
(Quarterly Results - Jun 2025)
Net Profit:
15 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-20.42%
0%
-20.42%
6 Months
6.45%
0%
6.45%
1 Year
-18.33%
0%
-18.33%
2 Years
-53.74%
0%
-53.74%
3 Years
-53.73%
0%
-53.73%
4 Years
-77.54%
0%
-77.54%
5 Years
-84.0%
0%
-84.0%
Shenzhen Kangtai Biological Products Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.08%
EBIT Growth (5y)
-55.78%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
1.71
Net Debt to Equity (avg)
0.19
Sales to Capital Employed (avg)
0.25
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
49.86%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.16%
ROE (avg)
6.62%
Valuation key factors
Factor
Value
P/E Ratio
196
Industry P/E
Price to Book Value
1.50
EV to EBIT
1371.09
EV to EBITDA
33.71
EV to Capital Employed
1.52
EV to Sales
4.97
PEG Ratio
NA
Dividend Yield
0.70%
ROCE (Latest)
0.11%
ROE (Latest)
0.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
732.80
641.10
14.30%
Operating Profit (PBDIT) excl Other Income
68.10
131.10
-48.05%
Interest
29.30
29.50
-0.68%
Exceptional Items
0.10
0.00
Consolidate Net Profit
15.20
22.40
-32.14%
Operating Profit Margin (Excl OI)
-48.50%
42.90%
-9.14%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 14.30% vs 3.34% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -32.14% vs 114.98% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,621.20
3,451.80
-24.06%
Operating Profit (PBDIT) excl Other Income
468.70
1,015.50
-53.85%
Interest
124.50
114.10
9.11%
Exceptional Items
1.40
0.20
600.00%
Consolidate Net Profit
201.60
861.30
-76.59%
Operating Profit Margin (Excl OI)
44.00%
224.50%
-18.05%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -24.06% vs 10.04% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -76.59% vs 749.06% in Dec 2023
About Shenzhen Kangtai Biological Products Co., Ltd. 
Shenzhen Kangtai Biological Products Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






